Brain Storms: The Race to Unlock the Mysteries of Parkinson's Disease
Format: PDF / Kindle (mobi) / ePub
A star science journalist with Parkinson's reveals the inner workings of this perplexing disease
Seven million people worldwide suffer from Parkinson’s, and doctors, researchers, and patients continue to hunt for a cure. In Brain Storms, the award-winning journalist Jon Palfreman tells their story, a story that became his own when he was diagnosed with the debilitating illness.
Palfreman chronicles how scientists have worked to crack the mystery of what was once called the shaking palsy, from the earliest clinical descriptions of tremors, gait freezing, and micrographia to the cutting edge of neuroscience, and charts the victories and setbacks of a massive international effort to best the disease. He takes us back to the late 1950s and the discovery of L-dopa. He delves into a number of other therapeutic approaches to this perplexing condition, from partial lobotomies and deep brain stimulation to neural grafting. And he shares inspiring stories of brave individuals living with Parkinson’s, from a former professional ballet dancer who tricks her body to move freely again to a patient who cannot walk but astounds doctors when he is able to ride a bicycle with no trouble at all.
With the baby boom generation beginning to retire and the population steadily aging, the race is on to discover a means to stop or reverse neurodegenerative conditions like Parkinson’s and Alzheimer’s. Brain Storms is the long-overdue, riveting, and deeply personal story of that race, and a passionate, insightful, and urgent look into the lives of those affected.
Parkinson’s; surgery just about vanished.” But by the late 1980s, as increasingly large numbers of patients around the world began to confront serious and intractable L-dopa-induced motor complications—the involuntary movements and sudden gait freezing—some surgeons started to offer surgical options to patients again. Lauri Laitinen, a Finnish surgeon working in Sweden, had also devised a safer and more effective way of performing pallidotomies. Meanwhile, Mahlon DeLong’s classic experiments
patients in the trial might have accumulated too much amyloid beta and developed too much brain damage to respond to these therapies. This argument is analogous to Jeff Kordower’s suggestion that gene therapy with growth factors for Parkinson’s disease had failed because by four or five years post-diagnosis the damage to the dopaminergic fibers was too extensive. Alzheimer’s researchers, however, have risen to the challenge. They wondered if there might be a way to deliver these plaque-busting
University of Tel Aviv to explore M13’s therapeutic properties, Solomon and Hillerstrom reached out to investors willing to bet on M13’s potential therapeutic powers. By January 2008, they had raised over $7 million and started hiring staff. Their first employee—NeuroPhage’s chief scientific officer—was Richard Fisher, a veteran of five biotech start-ups. Fisher recalls feeling unconvinced when he first heard about the miraculous phage. “But the way it’s been in my life is that it’s really all
solve: Chemists’ favorite metaphor for how protein folding may work is a group of skiers descending a snowy slope. Skiers may choose different paths down the mountain, but thanks to gravity and the tapered shape of the piste, they all end up at the ski lift at the bottom. In the same way, proteins may start off folding in many different patterns, but however they start off, they are all forced down a predesigned “energy slope,” and (without having to try every shape) they quickly—in a matter of a
dystonia chromosome 4 chromosome 14 chromosome 21 cingulate cortex Civitas Clifford, Rich clinical trials for Alzheimer’s of exercise FDA mandate for of GDNF of neural grafts new protocols for of NTN phases of recruitment for clinicians Clinton, Bill cocaine codeine coenzyme Q10 coffee Cogane cognitive impairment Collins, Frank Colombia Columbia-Presbyterian Medical Center, New York Columbia University Medical Center, Motor Performance Laboratory at Comber, Thomas